What this is
A reference on pharmaceutical competitive intelligence practice: how CI teams track pipelines at indication level, cover oncology congresses, combine published sources with primary expert research, and turn that into decisions a commercial team can act on.
It is written for people doing the work — CI analysts, brand and commercial teams, market access, and business development diligence — rather than for buyers of CI services. Where a topic has a commercial answer, that gets noted, but the material is meant to be useful to someone building the capability in house.
Who writes it
Delores Wong writes the blog entries here on pharmaceutical competitive intelligence.
Scope
Everything here draws on publicly available material: trial registries, congress proceedings, regulatory documents and company disclosure. No confidential or non-public competitor information is used, sought or published, and the articles on primary research set out plainly where that line sits.
Nothing on this site is clinical, regulatory, legal or investment advice.
Corrections
Pharmaceutical development moves and this material will age. If something here is wrong or out of date, corrections are welcome and will be made with the change noted rather than quietly.